LEBANON, N.H.--(BUSINESS WIRE)--Adimab, LLC, a leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced its 3rd technology transfer, by licensing the Adimab technology to Novo Nordisk. Adimab will receive upfront payments, annual licensing fees and royalties on commercialized products resulting from Novo Nordisk’s use of the Adimab technology. Under the agreement, Novo Nordisk has been granted a non-exclusive license to use Adimab’s antibody platform for the discovery and optimization of antibodies.
Help employers find you! Check out all the jobs and post your resume.
